Medicines labeled for the same conditions
Alternatives to canagliflozin
13 other medicines are given the same way (oral) and in the same FDA class as canagliflozin or labeled mainly for the same use (heart attack and coronary artery disease); 8 are in its class, sodium-glucose cotransporter 2 inhibitors: dapagliflozin, dapagliflozin and metformin, empagliflozin, empagliflozin and metformin and 4 more; the others include 3 HMG-CoA reductase inhibitors, 1 glp-1 receptor agonist and 1 adenosine triphosphate-citrate lyase inhibitor (FDA labels read October 8, 2026). In the same class, the lowest pharmacy cost is $0.184 per dapagliflozin 10 mg tablet (what pharmacies paid in the NADAC survey; strengths differ).
Which medicines are labeled for the same conditions as canagliflozin?
Heart attack and coronary artery disease lists all 38 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (oral) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Canagliflozinsodium-glucose cotransporter 2 inhibitor | this medicine | none listed | $19.13 per tablet 100 mg tablet | No | No current entry |
| Dapagliflozinsodium-glucose cotransporter 2 inhibitor · same class | Type 2 diabetes, Chronic kidney disease | 22 labelers | $0.184 per tablet 10 mg tablet | No | No current entry |
| Dapagliflozin and metforminsodium-glucose cotransporter 2 inhibitor · same class | Type 2 diabetes | 8 labelers | $0.720 per tablet 10-1,000 mg tablet | Yes | No current entry |
| Empagliflozinsodium-glucose cotransporter 2 inhibitor · same class | Type 2 diabetes, Chronic kidney disease | none listed | $11.19 per tablet 10 mg tablet | No | No current entry |
| Empagliflozin and metforminsodium-glucose cotransporter 2 inhibitor · same class | Type 2 diabetes | none listed | $5.60 per tablet 12.5-1,000 mg tablet | Yes | No current entry |
| Empagliflozin and linagliptin and metforminsodium-glucose cotransporter 2 inhibitor · same class | Type 2 diabetes | none listed | $11.28 per tablet 10-5-1,000 mg tablet | Yes | No current entry |
| Bexagliflozinsodium-glucose cotransporter 2 inhibitor · same class | Type 2 diabetes | none listed | n/a | No | No current entry |
| Empagliflozin and linagliptinsodium-glucose cotransporter 2 inhibitor · same class | Type 2 diabetes | none listed | $11.24 per tablet 10 mg-5 mg tablet | No | No current entry |
| Dapagliflozin and saxagliptinsodium-glucose cotransporter 2 inhibitor · same class | Type 2 diabetes | 1 labeler | n/a | No | No current entry |
| RosuvastatinHMG-CoA reductase inhibitor | Heart attack and coronary artery disease | 46 labelers | $0.0692 per tablet 40 mg tablet | No | No current entry |
| PravastatinHMG-CoA reductase inhibitor | Heart attack and coronary artery disease | 37 labelers | $0.058 per tablet 20 mg tablet | No | No current entry |
| SimvastatinHMG-CoA reductase inhibitor | Heart attack and coronary artery disease | 27 labelers | $0.0321 per tablet 20 mg tablet | No | No current entry |
| SemaglutideGLP-1 receptor agonist | Heart attack and coronary artery disease, Type 2 diabetes | none listed | $33.13 per tablet 1.5 mg tablet | Yes | A presentation being discontinued |
| Bempedoic acidadenosine triphosphate-citrate lyase inhibitor | Heart attack and coronary artery disease | none listed | $13.81 per tablet 180 mg tablet | No | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What do pharmacies pay for each?
The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Canagliflozin: the full record
- label, generics, price, shortages, recalls